免疫激活是肝细胞癌钇-90放射栓塞持续临床缓解的基础
本研究采用飞行时间质谱流式细胞术和二代测序分析钇-90放射栓塞治疗前后肝细胞癌患者的肿瘤浸润白细胞、肿瘤组织及外周血单个核细胞的免疫图谱。结果显示治疗后出现局部和全身免疫激活,并与持续缓解相关;基于治疗前外周血免疫特征构建了预测持续缓解者的模型。
要点
- 钇-90放射栓塞后肿瘤浸润白细胞显示局部免疫激活:颗粒酶B表达增高,CD8+ T细胞、CD56+ NK细胞和CD8+CD56+ NKT细胞浸润增加。
- 治疗后外周血CD8+和CD4+ T细胞肿瘤坏死因子-α增加,抗原提呈细胞百分比升高,提示全身免疫激活。
- 高比例的PD-1+/Tim-3+CD8+ T细胞共表达归巢受体CCR5和CXCR6与钇-90放射栓塞缓解者相关。
核心结论
- 对肿瘤和全身免疫景观的高维分析识别出与钇-90放射栓塞持续缓解相对应的局部和全身免疫激活。
- 研究识别了与阳性临床缓解相关的潜在生物标志物,并构建了治疗前识别持续缓解者的预测模型。
研究设计与样本
- 研究采用飞行时间质谱流式细胞术和二代测序分析钇-90放射栓塞治疗前后不同时间点的肿瘤浸润白细胞、肿瘤组织和外周血单个核细胞的免疫景观。
主要发现
- 钇-90放射栓塞后分离的肿瘤浸润白细胞显示局部免疫激活迹象:颗粒酶B表达增高,CD8+ T细胞、CD56+ NK细胞和CD8+CD56+ NKT细胞浸润增加。
- 二代测序证实钇-90放射栓塞治疗的肿瘤中固有免疫和适应性免疫激活相关基因上调。
- 涉及CCL5和CXCL16的趋化通路与活化的颗粒酶B+CD8+ T细胞募集至钇-90放射栓塞治疗的肿瘤相关。
- 比较钇-90放射栓塞前后外周血单个核细胞,观察到CD8+和CD4+ T细胞上肿瘤坏死因子-α增加,以及治疗后抗原提呈细胞百分比升高。
- 高比例的PD-1+/Tim-3+CD8+ T细胞共表达归巢受体CCR5和CXCR6标志着钇-90放射栓塞缓解者。
关键数值与推荐
- 基于治疗前外周血单个核细胞的免疫特征构建了预测模型,用于识别钇-90放射栓塞的持续缓解者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Yttrium-90 (Y90)-radioembolisation (RE) significantly regresses locally advanced hepatocellular carcinoma and delays disease progression. The current study is designed to deeply interrogate the immunological impact of Y90-RE, which elicits a sustained therapeutic response. DESIGN: Time-of-flight mass cytometry and next-generation sequencing (NGS) were used to analyse the immune landscapes of tumour-infiltrating leucocytes (TILs), tumour tissues and peripheral blood mononuclear cells (PBMCs) at different time points before and after Y90-RE. RESULTS: TILs isolated after Y90-RE exhibited signs of local immune activation: higher expression of granzyme B (GB) and infiltration of CD8+ T cells, CD56+ NK cells and CD8+ CD56+ NKT cells. NGS confirmed the upregulation of genes involved in innate and adaptive immune activation in Y90-RE-treated tumours. Chemotactic pathways involving CCL5 and CXCL16 correlated with the recruitment of activated GB+CD8+ T cells to the Y90-RE-treated tumours. When comparing PBMCs before and after Y90-RE, we observed an increase in tumour necrosis factor-α on both the CD8+ and CD4+ T cells as well as an increase in percentage of antigen-presenting cells after Y90-RE, implying a systemic immune activation. Interestingly, a high percentage of PD-1+/Tim-3+CD8+ T cells coexpressing the homing receptors CCR5 and CXCR6 denoted Y90-RE responders. A prediction model was also built to identify sustained responders to Y90-RE based on the immune profiles from pretreatment PBMCs. CONCLUSION: High-dimensional analysis of tumour and systemic immune landscapes identified local and systemic immune activation that corresponded to the sustained response to Y90-RE. Potential biomarkers associated with a positive clinical response were identified and a prediction model was built to identify sustained responders prior to treatment.
引用
- Chew V, Lee YH, Pan L, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. 2018. PMID: 29440463. doi:10.1136/gutjnl-2017-315485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。